Virco: looking into the future of AIDS therapy

Published By Datamonitor

Vinka alkaloids: market to fall 17% by 2007

Published By Datamonitor

Vertex: Positive results for cystic fibrosis drug

Vertex has completed a Phase II trial of a small-molecule oral drug, VX-770, which targets the basic defect that occurs in cystic fibrosis (CF). The trial has only been performed in 20 patients from a small, genetically distinct subset of the CF population. However, the results are encouraging and indicate an alternative approach to traditional reactive management of CF.

Published By Datamonitor

Vertex Pharmaceuticals: strong evidence for VX-770 as a potential novel treatment method

Vertex Pharmaceuticals' novel cystic fibrosis treatment VX-770 has demonstrated strong efficacy in a Phase III trial, meeting the primary endpoint and key secondary endpoints. VX-770 targets the underlying cause of the disease, and, if approved, would offer a novel treatment approach.

Published By Datamonitor

Verta/SciClone: new drug could limit TB spread

According to preliminary results, Russian pharma company Verta's new immune system enhancing drug may have a significant impact on TB contagion. Although the treatment regime is arduous, involving five daily injections, there could be a significant market for SCV-07 in locations where Directly Observed Treatment can be implemented.

Published By Datamonitor

Vernalis: revised R&D focus after Frova decision hits home

Vernalis's decision to undergo major restructuring is a direct result of the non-approval of the company's sNDA submission for Frova, for the treatment of menstrual migraine. A successful application had been anticipated to double the revenue potential of Frova.

Published By Datamonitor

Vernalis: Frovelan concerns a headache for shareholders

Published By Datamonitor

Vernalis: benefiting from SB's regulatory headaches

Published By Datamonitor

Vernalis/Endo: gain in menstrual migraine

New phase III data have confirmed previous results showing Vernalis and Endo's Frova to be an effective preventative treatment for menstrual migraine. This should pave the way for the migraine drug's approval in this additional indication. Anticipated in 2007, this approval is then expected to transform Frova's sales significantly.

Published By Datamonitor

Vectibix's possible label expansion may only lead to a modest increase in uptake

Amgen has received a positive opinion from the CHMP for Vectibix in combination with chemotherapy in the first- and second-line treatment of mCRC. This is a significant step forward for Vectibix, but if it is approved, market competition will result in only a modest increase in uptake and commercial reward.

Published By Datamonitor